These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 12790142)

  • 1. Rapamycin throws a master switch.
    Josephson J
    Environ Health Perspect; 2003 May; 111(6):A335. PubMed ID: 12790142
    [No Abstract]   [Full Text] [Related]  

  • 2. [Primary study of vasculogenic mimicry induced by hypoxia in epithelial ovarian carcinoma].
    Yao LQ; Feng YJ; Ding JX; Xu CJ; Jin HY; Yin LH
    Zhonghua Fu Chan Ke Za Zhi; 2005 Oct; 40(10):662-5. PubMed ID: 16277894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature.
    Moccia F; Fotia V; Tancredi R; Della Porta MG; Rosti V; Bonetti E; Poletto V; Marchini S; Beltrame L; Gallizzi G; Da Prada GA; Pedrazzoli P; Riccardi A; Porta C; Zambelli A; D'Incalci M
    Eur J Cancer; 2017 May; 77():155-164. PubMed ID: 28258798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.
    Shirouzu Y; Ryschich E; Salnikova O; Kerkadze V; Schmidt J; Engelmann G
    J Surg Res; 2010 Apr; 159(2):705-13. PubMed ID: 19482307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of rapamycin (Sirolimus, Rapamune).
    Molnar-Kimber KL
    Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.
    El-Hashemite N; Zhang H; Henske EP; Kwiatkowski DJ
    Lancet; 2003 Apr; 361(9366):1348-9. PubMed ID: 12711473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin induces Smad activity in prostate cancer cell lines.
    van der Poel HG; Hanrahan C; Zhong H; Simons JW
    Urol Res; 2003 Feb; 30(6):380-6. PubMed ID: 12599018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
    Böhm A; Aichberger KJ; Mayerhofer M; Herrmann H; Florian S; Krauth MT; Derdak S; Samorapoompichit P; Sonneck K; Vales A; Gleixner KV; Pickl WF; Sperr WR; Valent P
    Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells.
    Kao CL; Hsu HS; Chen HW; Cheng TH
    Cancer Lett; 2009 Dec; 286(2):250-9. PubMed ID: 19560264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of rapamycin in gliomas.
    Heimberger AB; Wang E; McGary EC; Hess KR; Henry VK; Shono T; Cohen Z; Gumin J; Sawaya R; Conrad CA; Lang FF
    Neuro Oncol; 2005 Jan; 7(1):1-11. PubMed ID: 15701277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.
    Stoeltzing O; Meric-Bernstam F; Ellis LM
    Cancer Cell; 2006 Aug; 10(2):89-91. PubMed ID: 16904605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swinging the vote for rapamycin.
    Novak K
    Nat Rev Cancer; 2002 Feb; 2(2):75. PubMed ID: 12635162
    [No Abstract]   [Full Text] [Related]  

  • 14. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma.
    Yang C; Zhang Y; Zhang Y; Zhang Z; Peng J; Li Z; Han L; You Q; Chen X; Rao X; Zhu Y; Liao Z
    Int J Oncol; 2015 Sep; 47(3):909-17. PubMed ID: 26202311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
    Geoerger B; Kerr K; Tang CB; Fung KM; Powell B; Sutton LN; Phillips PC; Janss AJ
    Cancer Res; 2001 Feb; 61(4):1527-32. PubMed ID: 11245461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer.
    Stephan S; Datta K; Wang E; Li J; Brekken RA; Parangi S; Thorpe PE; Mukhopadhyay D
    Clin Cancer Res; 2004 Oct; 10(20):6993-7000. PubMed ID: 15501979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells.
    Shigematsu H; Yoshida K; Sanada Y; Osada S; Takahashi T; Wada Y; Konishi K; Okada M; Fukushima M
    Int J Cancer; 2010 Jun; 126(11):2716-25. PubMed ID: 19856312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.
    Brown VI; Fang J; Alcorn K; Barr R; Kim JM; Wasserman R; Grupp SA
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15113-8. PubMed ID: 14657335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining sensitivity to rapamycin and its analogues in breast cancer patients.
    Witton CJ
    Breast Cancer Res; 2005; 7(1):41-2. PubMed ID: 15642182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.